If You Invested in ACOR (ACOR)
Looking for the current price? See the ACOR quote & overviewWhat $1,000 or $10,000 in ACOR Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 15, 2015 |
|---|---|---|---|---|
| $1,000 | — | $4 -100% | $0 -100% | $0 -100% |
| $10,000 | — | $35 -100% | $1 -100% | $1 -100% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for ACOR$1,000 Investment Over Time
ACOR vs S&P 500Year-by-Year Returns
ACOR annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015 | $4258.80 | $5133.60 | +20.5% | +20.5% |
| 2016 | $5070.00 | $2256.00 | -55.5% | -47.0% |
| 2017 | $2340.00 | $2574.00 | +10.0% | -39.6% |
| 2018 | $2718.00 | $1869.60 | -31.2% | -56.1% |
| 2019 | $1946.40 | $244.80 | -87.4% | -94.3% |
| 2020 | $235.20 | $82.81 | -64.8% | -98.1% |
| 2021 | $76.00 | $47.80 | -37.1% | -98.9% |
| 2022 | $50.00 | $15.33 | -69.3% | -99.6% |
| 2023 | $15.70 | $15.09 | -3.9% | -99.6% |
| 2024 | $14.95 | $0.28 | -98.2% | -100.0% |
About ACOR
Manufacturing · NASDAQ
Acorda Therapeutics, Inc. (ACOR) develops and commercializes therapies for neurological disorders. The company is centered on approved products for Parkinson’s disease and multiple sclerosis, together with a pulmonary drug-delivery technology used in one of its commercial products. Its business has been described through product revenue, commercialization arrangements, clinical or regulatory disclosures, material agreements, capital-structure matters, governance updates, and operating and financial results.
The company’s principal product references include INBRIJA, a levodopa inhalation powder approved for the intermittent treatment of OFF episodes in adults with Parkinson’s disease who are treated with carbidopa/levodopa. INBRIJA uses Acorda’s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets AMPYRA, branded dalfampridine extended-release tablets, 10 mg, for the U.S. market.
Acorda’s product and rights portfolio also includes FAMPYRA, the fampridine brand indicated in the European Union and other territories for improvement of walking in adults with multiple sclerosis with walking disability. Company communications have described commercialization and supply responsibilities for neurological therapies across the United States and international territories, including product revenue from INBRIJA and AMPYRA and royalty or commercialization arrangements associated with FAMPYRA.
Acorda is headquartered in Pearl River, New York. Its public-company materials identify the company with the ACOR ticker and focus on the development, approval status, commercialization, and financial performance of therapies intended to address functional impairment in neurological disease.
Frequently Asked Questions
ACOR investment returns
How much would $1,000 invested in ACOR be worth today?
If you invested $1,000 in ACOR (ACOR) 10 years ago on 2016-07-14, your investment would be worth $0 today, representing a -100.0% total return, growing at a compounded rate of -69.1% per year (CAGR).
Has ACOR outperformed the S&P 500?
Over the past 10 years, ACOR returned -100.0% compared to +246.6% for the S&P 500, underperforming the benchmark by 346.6 percentage points.
What is ACOR's average annual return?
The compound annual growth rate (CAGR) of ACOR over the past 10 years is -69.1%, growing at a compounded rate each year. Individual years vary significantly — ACOR's best recent year was 2015 (+20.5%) and worst was 2024 (-98.2%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
